PROPOSAL BY THE BOARD OF DIRECTORS FOR RESOLUTIONS AT THE ANNUAL GENERAL MEETING ON 17 APRIL 2023

9b. Resolution with respect to disposition of the Company's result according to the adopted Balance Sheet

The Board of Directors proposes that no dividend be paid for the financial year 2022 and that the Company's available funds be capitalized in a new account.

16. Resolution regarding incentive program ("LTI II 2023")

Background and reasons

The Company has previously implemented long term incentive programs for the years of 2021 and 2022. In view of this, the Board of Directors proposes that the Annual General Meeting resolves to implement a long term incentive program for the members of the group management, key employees, other employees and consultants in the Company and within the group ("LTI II 2023"). The proposal to implement an incentive program has been put forward as the Board of Directors determines that it is important and in the interest of all shareholders to create even greater participation for current and future members of the group management, key employees and other employees and consultants in the Company and the group with regard to the group's development. It is also important to encourage continued employment and service.

In the light of the above, the Board of Directors proposes that the Annual General Meeting resolves to implement the incentive program LTI II 2023 in accordance with item (a)–(b) below. The resolutions under item (a)–(b) below are proposed to be conditional upon each other and for that reason it is proposed that all resolutions are to be passed as one resolution. LTI II 2023 is proposed to include up to approximately 668 current and future members of the group management, key employees, other employees and consultants within the Olink group.

Proposal regarding the adoption of LTI II 2023 (item 16 (a))

LTI II 2023 is comprised of stock options and restricted stock units ("RSU") which will be granted to current and future members of the group management, key employees, employees and consultants within the Olink group pursuant to the Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan (the "Plan"), as amended, and an award agreement thereunder to be entered into between the Company and each recipient evidencing each such grant and terms under the Plan. On 14 March 2023, the Board adopted, subject to the approval of the Company's shareholders, an amendment to the Plan, which will become effective on the date of its approval by the Company's shareholders, which will occur upon approval by the Company's shareholders of LTI I 2023 and LTI II 2023 as described herein. The purpose of the amendment to the Plan is to increase the maximum number of shares available for issuance under the Plan in order to ensure that there is a sufficient number of shares available for grant pursuant to LTI I 2023 and LTI II 2023 as described herein

The Board of Directors proposes that the general meeting resolves to issue not more than 910,000 warrants of series II 2023 in order to secure delivery of either shares, warrants of series II 2023 or American depository shares in the Company ("ADS") upon exercise of stock options or RSUs to participants in LTI II 2023. The right to subscribe for the warrants of Series II 2023 shall vest in the Company. The Company shall keep warrants of Series II 2023 to ensure delivery of shares, warrants of series II 2023 or ADS upon exercise of stock options in LTI II 2023. Each warrant of series II 2023

entitles the holder to subscribe for one (1) share in the Company. The warrants of series II 2023 shall be issued without consideration to the Company.

Below is a description of the terms and conditions for the LTI II 2023 A copy of the Plan can be found at https://investors.olink.com/annual-general-meeting and shareholders are advised to review the actual terms of the Plan.

LTI II 2023 – Stock options (with warrants as hedging arrangement)

Each stock option entitles the participant to acquire either one (1) share in the Company, one (1) warrant of series II 2023 or one (1) ADS in accordance with the following terms and conditions:

- Stock options may be granted to current and future members of the group management, key employees, other employees and consultants within the Olink group;
- The stock options of LTI II 2023 will be granted without consideration no later than the day before the next Annual General Meeting;
- Each stock option entitles the holder to acquire either one (1) share, warrant of series II
 2023 or ADS in the Company at an exercise price equal to 100 per cent to the fair market
 value of the share, as determined by the closing price of the Company's ADS on the Nasdaq
 Global Market on the relevant grant date or in the absence of any sale on such date the
 immediately preceding date on which a sale occurred;
- The stock options are subject to time based vesting requirements on the date when a portion of the options would vest as a result of the passage of time with the participant remaining employed or engaged by the Olink group;
- The stock options will vest and become exercisable in equal installments on 7 April 2024, 7 April 2025, 7 April 2026 and 7 April 2027 provided the participant remain employed or engaged by the Olink group at the applicable vesting dates. As a main rule each vesting period shall be twelve (12) months. All granted stock options will, as a general rule, have vested (if applicable) on 7 April 2027, i.e, a vesting period of four (4) years. In the event that the period between the grant date and the first vesting date is less than ten (10) months for any participant, the Board is entitled to decide on a separate vesting schedule for the participant with conditions substantially equivalent to those set out in this proposed resolution;
- The stock options may not be transferred or pledged;
- Upon vesting, unless the participants engagement as members of the group management, key employees, other employees and consultants within the Olink group ends sooner, stock options remain exercisable for a period of four (4) years from the first vesting date.
 However, the participants may only exercise vested stock options during certain exercise windows as set out in separate option agreements; and
- The terms and conditions for participants in LTI II 2023 granted stock options may differ between countries due to differences in local legislation, however the terms and conditions shall not be more favorable for participants than what is set out in this resolution proposal.

LTI II 2023 – Restricted stock units (with warrants as hedging arrangement)

Within the scope of LTI II 2023, the Company may also grant participants RSUs, entailing the right to, subject to certain conditions being met, receive either a share, warrant of series II 2023 or an ADS free of charge or to an exercise price equal to the quota value of the Company's share, at the time of exercise of the RSU.

- RSUs may be granted to current and future members of the group management, key employees, other employees and consultants within the Olink group;
- The RSUs will be granted without consideration no later than the day before the next Annual General Meeting;
- The RSUs granted will be subject to time based vesting requirements on the date when a portion of the RSUs would vest as a result of the passage of time with the participant remaining employed or engaged by the Olink group;
- The RSUs will vest in equal installments on 7 April 2024, 7 April 2025, 7 April 2026 and 7 April 2027 provided the participant remain employed or engaged by the Olink group at the applicable vesting dates and the holders of RSUs will receive a share, ADS or warrant of series LTI II 2023 in settlement of the RSUs following the applicable vesting date. As a main rule each vesting period shall be twelve (12) months. All granted RSUs will, as a general rule, have vested (if applicable) on 7 April 2027, i.e., a vesting period of four (4) years. In the event that the period between the grant date and the first vesting date is less than ten (10) months for any participant, the Board is entitled to decide on a separate vesting schedule for the participant with conditions substantially equivalent to those set out in this proposed resolution;
- The RSUs may not be transferred or pledged; and
- The terms and conditions for participants in LTI II 2023 granted RSUs may differ between countries due to differences in local legislation, however the terms and conditions shall not be more favorable for participants than what is set out in this resolution proposal.

The warrants issued to the Company in order to secure delivery of shares, warrants of series II 2023 or ADS upon exercise of stock options or settlement of RSUs granted to participants in LTI II 2023 may be exercised for subscription of shares during the period from and during the period commencing on the date of the registration of the issue resolution with the Swedish Companies Registration Office up to and including the date ten (10) years after the registration of the issue resolution with the Swedish Companies Registration Office, at an exercise price equal to the shares' quota value, at the time of exercise.

Allocation of stock options and RSUs, limitations in the disposition over the stock options and the RSUs and the right to receive stock options and RSUs

The participants' right to be granted stock options and RSUs have been differentiated with reference to position, responsibility and working performance in the group and the participants have for this reason been divided into four different categories:

Category A (Management) – Members of the group management;

Category B (Tier I) – Key employees;

Category C (Tier II) - Other employees and consultants; and

Category D (Tier III) – Other individual contributors

The right to receive stock options or RSUs under LTI II 2023 shall vest in members of the group management, key employees, other employees and consultants employed or engaged by the Company or the group. The following allocation applies to the grant of stock options and RSUs within each category.

	Maximum number of stock options/RSUs for each participant	Total number of stock options/RSUs within the category
Category A – not more than 11 people	15,000/65,000	70,000/200,000
Category B – not more than 27 people	0/10,000	0/120,000
Category C – not more than 250 people	0/5,000	0/370,000
Category D – not more than 380 people	0/2,000	0/150,000

In total, a maximum of 840,000 RSUs and 70,000 stock options may be granted to participants.

In the event that all stock options or RSUs within category A, B or C are not transferred, such non-transferred stock options or RSUs may be offered to participants in another category with less stock options and/or RSUs available for allotment. The maximum number of stock options or RSUs per person within each category as set out above may however not be exceeded for any individual.

Proposal regarding issue of warrants of series II 2023 (item 16 (b))

The Board of Directors proposes that the Company shall issue not more than 910,000 warrants of series II 2023 for subscription of shares, whereby the Company's share capital may be increased by not more than SEK 2,213,035.02 at full exercise of warrants for subscription of shares, corresponding to approximately 0.73 per cent of the total number of shares and votes in the Company.

The right to subscribe for the warrants of series II 2023 shall, with deviation from the shareholders' preferential rights, only belong to the Company, with the right and obligation to dispose of the warrants of series II 2023 as described above. The subscription for warrants shall be made up to and including 15 May 2023. Each warrant of series II 2023 entitles the holder to subscribe for one (1) share in the Company. The warrants of series II 2023 shall be issued without compensation to the Company.

The warrants may be exercised for subscription of shares during the period from and during the period commencing on the date of the registration of the issue resolution with the Swedish Companies Registration Office up to and including the date ten (10) years after the registration of the issue resolution with the Swedish Companies Registration Office, at an exercise price equal to the shares' quota value, at the time of exercise.

In order to fulfil the commitments arising from LTI II 2023, the Board of Directors proposes that the general meeting authorizes that the Company may assign to a third party or in another way dispose of the warrants of series II 2023 in accordance with above.

A detailed resolution proposal for the issue of warrants of series II 2023, including complete terms and conditions for the warrants, is set out in Appendix A (including its sub-appendix).

Recalculation due to split, consolidation, new share issue etc.

The exercise price for warrants in LTI II 2023, determined as set out above, shall be rounded to the nearest SEK 0.10 whereby SEK 0.05 shall be rounded upwards. The exercise price and/or the number of shares that each warrant entitles to subscription for may be recalculated in the event of a split or reverse split of shares in accordance with customary re-calculation terms

Costs

The stock options are expected to incur accounting costs (accounted for in accordance with the accounting standard IFRS 2) as well as social security costs during the term of the stock options. According to IFRS 2, the stock option costs shall be recorded as a personnel expense in the income statement during the vesting period. The total costs for 70,000 stock options, calculated in accordance with IFRS 2, are estimated to amount to approximately SEK 8.8 million during the term of the program (excluding social security costs). The estimated costs have been calculated based on, inter alia, the following assumptions: (i) a market price of the Company's share/ADS of USD 24.11, equivalent to SEK 252.70, at the time of grant, based on a USD-SEK exchange rate of 10.4813, (ii) an estimated future volatility in respect of the Company's share/ADS during the term of the stock options of 71 per cent, (iii) that the maximum number of stock options encompassed by this resolution proposal are granted to participants and (iv) that all granted stock options will vest and be exercised. Social security costs, which are expected to arise primarily in connection with the exercise of stock options, are estimated to amount to approximately SEK 1.3 million during the term of the program, based on inter alia the assumptions set out under items (i)—(iv) above as well as an average social security rate of 15 per cent.

The RSUs are expected to incur accounting costs (accounted for in accordance with the accounting standard IFRS 2) as well as social security costs during the term of the RSUs. According to IFRS 2, the RSUs costs shall be recorded as a personnel expense in the income statement during the vesting period. The total costs for 840,000 RSUs, calculated in accordance with IFRS 2, are estimated to amount to approximately SEK 212.3 million during the term of the program (excluding social security costs). The estimated costs have been calculated based on, inter alia, the following assumptions: (i) a market price of the Company's share/ADS of USD 24.11, equivalent to SEK 252.7, at the time of grant, based on a USD-SEK exchange rate of 10.4813, (ii) that the maximum number of RSUs encompassed by this resolution proposal are granted to participants, (iii) that all granted RSUs will vest and (iv) that holders of RSUs receive a share, ADS or warrant of series LTI II 2023. Social security costs, which are expected to arise primarily in connection with holders of RSUs receive a share, ADS or warrant of series LTI II 2023, are estimated to amount to approximately SEK 70.1 million during the term of the program, based on inter alia the assumptions set out under items (i)—(iv) above as well as an average social security rate of 23 per cent and an annual increase in the market price of the Company's share/ADS of 15 per cent during the vesting period.

Other costs related to the LTI II 2023, including inter alia expenses related to fees to external advisors, external appraiser and administration of the incentive program, are estimated to amount to approximately SEK 1.5 million during the term of the program.

Based on the assumptions set out above, the total costs of the LTI II 2023 are estimated to approximately SEK 293.9 million in total during the term of the program. These costs shall be seen in relation to the total employee benefits expenses of the Olink group, which during the financial year 2022 amounted to SEK 721 million.

Motivation in respect of vesting and exercise conditions

According to recommendations laid down by the Swedish Corporate Governance Board (Sw. *Kollegiet för svensk bolagsstyrning*), the vesting period, or the period between the date of grant until the date when a warrant or stock option may be exercised, shall as a general rule not be shorter than three (3) years. As set out further above, stock options will vest and become exercisable in equal installments on 7 April for four years and RSUs will vest in equal installments on 7 April for four years and holders of RSUs will receive a share, ADS or warrant, provided that all applicable vesting conditions have then been fulfilled. The reason for applying such terms, which are not in line with the recommendations of the Swedish Corporate Governance Board as set out above, is that the Board of Directors of the Company deem such terms to be in line with market practice for stock option programs in most of the countries where the intended participants in the LTI II 2023 are operative. It is therefore, in the opinion of the Board of Directors of the Company, in the best interest of the Company and its shareholders to apply such terms in order to fulfil the objectives of the LTI II 2023.

Dilution

Upon exercise of all warrants of series II 2023 issued within the frame of LTI II 2023 for subscription of shares, up to 910,000 shares (with reservation for any re-calculation) may be issued, equivalent to a maximum dilution of approximately 0.73 per cent of the shares and votes of the Company. Upon full exercise of warrants of series II 2023 for subscription of shares, the Company's share capital will increase with SEK 2,213,035.02. The dilution calculations have been based on the maximum number of shares and votes which may be issued upon exercise of the stock options and RSUs, divided by the total number of outstanding shares and votes in the Company as per 28 February 2023 after such issues.

Preparation of the proposal

The proposal to the incentive program LTI II 2023 has been prepared by the Remuneration Committee and the Board of Directors together with external advisers. The Company's board member and CEO Jon Heimer has not participated in the preparations of LTI II 2023.

The reason for the deviation from the shareholders' preferential rights

The reason for the deviation from the shareholders' preferential rights is to implement an incentive program for the members of the group management, key employees, other employees and consultants in the Company and the group.

Majority requirement

A resolution to approve the present proposal is valid only where supported by shareholders holding not less than nine-tenths (9/10) of both the shares voted for and of the shares represented at the general meeting.

Authorization

It is further proposed that the Board of Directors, or a person appointed by the Board of Directors, is authorized to undertake such minor adjustments in the decision that may be required for the

registration with the Swedish Companies Registration Office and Euroclear Sweden AB and that the Board of Directors shall have the right to undertake minor adjustments to the LTI II 2023 and the Plan due to applicable foreign rules and laws.

Outstanding incentive programs

The Company does have the following outstanding share-related incentive programs.

LTI 2021. A general meeting held on 16 March 2021 approved the majority shareholders' proposal regarding an incentive program for board members, members of the group management, key employees, other employees and consultants in the Company and within the group and resolution of issue of not more than 1,085,900 warrants and resolution of approving transfer of warrants. In total, 1,085,900 warrants were subscribed by the Company and 378,547 stock options and 333,601 RSUs have been acquired by or granted to participants. No more stock options or RSUs will be offered out of LTI 2021. The exercise price was set to USD 25 per share. Upon exercise of all stock options and RSUs which have been granted to participants and which have, as of the date of this resolution proposal, not yet been exercised, a maximum of 624,484 shares will be issued in the Company, equivalent to a dilution of approximately 0,50 per cent.

LTI I 2022. A general meeting held on 7 April 2022 approved the majority shareholders' proposal regarding an incentive program for board members in the Company and resolved on an issue of not more than 70,000 warrants and resolution of approving transfer of warrants. In total, 65,625 warrants were subscribed by the Company and 65,625 stock options have been acquired by or granted to participants. No more stock options will be offered out of LTI I 2022. The exercise price was set to USD 17.39 per share. Upon exercise of all stock options which have been granted to participants and which have, as of the date of this resolution proposal, not yet been exercised, a maximum of 65,625 shares will be issued in the Company, equivalent to a dilution of approximately 0.05 per cent.

LTI II 2022. A general meeting held on 7 April 2022 approved the board of directors' proposal regarding an incentive program for the members of the group management, key employees, other employees and consultants in the Company and within the group and resolved on an issue of not more than 797,514 warrants and resolution of approving transfer of warrants. In total, 797,514 warrants were subscribed by the Company and 41,448 stock options and 611,460 RSUs have been acquired by or granted to participants. No more stock options or RSUs will be offered out of LTI II 2022. The exercise price was set to USD 17.39 per share. Upon exercise of all stock options and RSUs which have been granted to participants and which have, as of the date of this resolution proposal, not yet been exercised, a maximum of 652,908 shares will be issued in the Company, equivalent to a dilution of approximately 0,52 per cent.

17. Resolution regarding authorization for the Board of Directors to resolve on a new issue

The Board of Directors proposes that the Annual General Meeting resolves to authorize the Board of Directors to, at one or several occasions and for the period up until the next Annual General Meeting, increase the Company's share capital by issuing new shares. Such share issue resolution may be carried out with or without deviation from the shareholders' preferential rights whereby payment can be made in cash and with or without provisions for contribution in kind, set-off or other conditions. The authorization may only be utilized to the extent that it corresponds to a dilution of not more than 20 per cent of the total number of shares based on the number of shares outstanding at the time of the general meeting's resolution on the proposed authorization.

The purpose of the authorization is to increase the financial flexibility of the Company and the general flexibility of the Board of Directors. Should the Board of Directors resolve on an issue with deviation

from the shareholders' preferential rights, the reason for this shall be to provide the Company with working capital and/or new owners of strategic importance to the Company and/or to procure capital to finance acquisitions of other companies or operations and/or to procure capital to finance the development of projects and/or to commercialize the Company's products. Upon such deviation from the shareholders' preferential rights, the new issue shall be made at market terms and conditions.

The Board of Directors, the CEO or the person that the Board appoints, shall have the right to make any adjustments in the decision required for registration.

The resolution proposed by the Board of Directors in accordance with item 17 must be approved by shareholders representing not less than two thirds of the votes cast and shares represented at the Annual General Meeting.

Appendix A

LTI II 2023 – ISSUE OF WARRANTS OF SERIES II 2023

The board of directors proposes an issue of not more than 910,000 warrants.

- 1. The right to subscribe for the warrants shall, with deviation from the shareholders' preferential rights, only vest in the Olink Holding AB (publ).
- 2. The warrants will be issued without consideration (Sw. vederlagsfritt).
- 3. The subscription for warrants shall be made up to and including 15 May 2023.
- 4. Upon exercise of all warrants in series II 2023 for subscription of shares, up to 910,000 shares (with reservation for any re- calculation) may be issued. Upon full exercise of the warrants in series II 2023 for subscription of shares, the Company's share capital will increase with a maximum of SEK 2,213,035.02.
- 5. Any share premium shall be transferred to the share premium fund
- 6. The warrants of series II 2023 shall in all other respects be governed by the terms and conditions set forth in Appendix A.1.

The reason for the deviation from shareholders' preferential right is to implement an incentive program for current and future members of the group management, key employees, other employees and consultants in the Company and the group.

It is furthermore proposed that the board of directors, or a person appointed by the board of directors, is authorized to undertake such minor adjustments in the resolution that may be required for the registration with the Swedish Companies Registration Office and Euroclear Sweden AB.